Navigation Links
Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
Date:8/11/2008

BEIJING, Aug. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, announced today that it will hold its 2007 Annual Meeting of Shareholders on Thursday, September 4, 2008 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC and at No. 6 Temple Street, St. John's, Antigua. All shareholders of record as of August 1, 2008 will be eligible to vote and are invited to attend.

Sinovac Biotech Ltd.'s 2007 Annual Report, notice of annual general meeting and proxy statement are available on the investors section of the Company's website http://www.sinovac.com .

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looki
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
9. Sinovac Biotech Holds Annual General Meeting
10. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...6 Intarcia Therapeutics, Inc. deli...OS® continuous delivery of exenatide) program... Annual Diabetes Technology Meeting in San Francis...in/prnh/20050301/SFTU126LOGO ) ,, Continuous ...wers Plasma Glucose, HbA1c and Reduces Weight in a...
(Date:11/5/2009)... 5 DSM Pharmaceutical Products tod...ance with Galenix, Saint Jean D,Illac, France, whe...facturing partner for Galenix commercial products ...aborate on business development opportunities co-m... on the strength of Galenix in drug product develo...
(Date:11/5/2009)... BioSpecifics Technologi...pany developing first-in-class collagenase-based p... the third quarter ended September 30, 2009. ,...his year, the FDA,s Arthritis Advisory Committee u...roval of XIAFLEX(TM) for the treatment of Dupuytre...
(Date:11/5/2009)... SpineSmith Partners has signed an ...p a unique scaffold that mimics the structure of n...everal commercial products by SpineSmith,s Researc... the GenOsteo scaffold represents a significant ad...ideal environment for the delivery of adult stem c...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2
... and Tragara Pharmaceuticals Inc. today announced ...se to Tragara to develop and commercialize its nov...terms of the agreement S*BIO is eligible to receiv...s an upfront fee, development and sales milestone ...onally, S*BIO will perform certain preclinical act...
... (Nasdaq: NLTX ), today announced that it will f...ic peptide franchise, including CD-NP which is in ...CU-NP which is a pre-clinical compound. Nile will ...urn license rights for the compound to Dr. Cesare ... unable to continue to pursue the development of 2...
...ex: DDD ) today announced that the U. S. Food an...Response letter for its Abbreviated New Drug Appli...n, filed by SCOLR on August 5, 2008, seeks approva...t based on its patented Controlled Delivery Techno...e letter requests additional information, all of w...
Other Biology Technology:S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317 2S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317 3Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 2Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 3Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 4FDA Issues Complete Response Letter to SCOLR Pharma's Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine 2FDA Issues Complete Response Letter to SCOLR Pharma's Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine 3
(Date:11/6/2009)...h anniversary this month of the publication of On ...iological Sciences (AIBS) is publishing open acces...and his historic insights into evolution. , The t...of California, Berkeley, and James T. Costa of Wes...yths About Charles Darwin," appeared in the Octobe...
(Date:11/5/2009)...ion of Biology Teachers (NABT) will recognize Leon... at Naugatuck Valley Community College (NVCC) in W...cation Award during the NABT annual professional d...09 in Denver, Colorado. , The Evolution Educatio...f Biological Sciences,(AIBS) and Biological Scien...
(Date:11/4/2009)...n natural science) , United States Using Less ... today than it did 35 years ago, despite a 30 perc... partly attributable to alternative cooling method...stems. According to the latest USGS water use repo...ates goes to cooling thermoelectric power plants. ...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Cardiac stem cell trial seeks to treat some heart attack patients 58592 1Cardiac stem cell trial seeks to treat some heart attack patients 58592 2Cardiac stem cell trial seeks to treat some heart attack patients 58592 3Study explores how life experiences contribute to the biological changes of Alzheimers 10197 1Study explores how life experiences contribute to the biological changes of Alzheimers 10197 2Study explores how life experiences contribute to the biological changes of Alzheimers 10197 3FDA Approves PRE PEN Penicillin Allergy Test 58590 1FDA Approves PRE PEN Penicillin Allergy Test 58590 2
...ctedly from the ocean to rescue a dying coral reef...dramatic flair of comic-book superhero Batman, a b...d to death by seaweed ?although the fish was never...s at the ARC Centre of Excellence for Coral Reef S...are lost to weed were astonished when, after remov...
...tic increase in testicular cancer, now the most co...asian men, is the focus of a five-year, $5.5 milli...ublic Health researcher Tongzhang Zheng. , Testicu...his study will provide important information on po...rs,?said Zheng, professor and head of the Division...
...any of them had narrow, pointed teeth, which were ...ing them. But how did they then grind their food? ...they were helped by stones which they swallowed. I...d of ,gastric mill,. But this assumption does not ...ies of Bonn and Tübingen have now proved. Their re...
Other Biology News:Batfish to the rescue! 2Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3
NucBuster Protein Extraction Kit from Novagen
... Synthetic peptide derived from the C-terminal reg...actor D iris-expressed growth factor spinal cord-d... mouse and rat by one amino acid replacement. Spe...rat PDGF-D proteins. Reactivity: Human (positive ...
Rabbit anti-USP33 AbVantage Pack Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Normal Rabbit Serum from Calbiochem
Biology Products: